- Open Access
On the significance of germline cytogenetic rearrangements at MYCN locus in neuroblastoma
© Lipska et al.; licensee BioMed Central Ltd. 2013
- Received: 19 July 2013
- Accepted: 20 September 2013
- Published: 16 October 2013
MYCN oncogene amplification is the most important prognostic factor in neuroblastoma. 25% neuroblastoma tumors have somatic amplifications at this locus but little is known about its constitutional aberrations and their potential role in carcinogenesis. Here, we have performed an array-CGH and qPCR characterization of two patients with constitutional partial 2p trisomy including MYCN genomic region.
One of the patients had congenital neuroblastoma and showed presence of minute areas of gains and losses within the common fragile site FRA2C at 2p24 encompassing MYCN. The link between 2p24 germline rearrangements and neuroblastoma development was reassessed by reviewing similar cases in the literature.
It appears that constitutional rearrangements involving chromosome 2p24 may play role in NB development.
- Partial 2p trisomy
Congenital chromosomal aberrations have been of help in identification of causative tumor suppressor gene (TSG) in oncology, to name just two most notorious: WT1 at 11p13.1 and RB1 at 13q14.1. Since constitutional deletions and translocations are often the first indicators of the presence of TSGs, the pursue for patients with neuroblastoma (NB) and a concomitant constitutional genomic disorder has started. Disappointingly, so far only a dozen of cases with a germinal chromosomal aberration have been reported to develop NB (Additional file 1: Table S1). Of these, only two regions were found to be affected repeatedly: a loss at chromosome 1p36 and a gain of chromosome 2p. Chromosome 1p36 is known to be deleted in ca. 30% of primary NB tumors, being one of the most common somatic cytogenetic abnormalities of recognizable prognostic significance [1, 2]. Accordingly, it has been proposed as the putative locus for NB TSG, however so far no major NB predisposition gene has been identified in this region .
Conversely, with respect to chromosome 2p two genes involved in NB pathogenesis came into play. Germinal activating mutation in ALK, an oncogene lying at chromosome 2p23 has been recognized responsible for most of the familial NB cases, while its somatic mutations are present in 8% of sporadic tumors . Then again, 2p24.3 is the locus of MYCN gene, amplification of which is considered the most important factor of poor prognosis in NB [5, 6]. Since no clear correlation between constitutional rearrangements involving chromosome 2p and the role of ALK and/or MYCN in early stages of NB pathogenesis has been established, in the current study we have evaluated our two cases and reviewed all reported NB with germinal cytogenetic rearrangements involving chromosome 2p. We used array-CGH and qPCR techniques for further delineation the minimal overlapping region, identification of the causative genes and their role in NB pathogenesis.
Two patients with constitutional aberration including partial 2p trisomy detected by classical cytogenetic studies were further evaluated using array-CGH. The patient with NB was found to have 20.5 Mb duplication (arr[hg18] 2p25.3p24.1(2,999-20,462,999)×3), while another patient had 22.3 Mb duplication (arr[hg18] 2p25.3p24.1(29,193-22,311,862)×3) at chromosome 2p together with a deletion on chromosome 18q (arr[hg18] 18q22.3q23(71,282,999-76,112,910)×1) and 17p (arr[hg18] 17p13.3(29,169-2,867,570)×1) respectively. In both cases region of gain encompassed MYCN genomic region but not locus of ALK gene.
Then again, the question arises, whether constitutional 2p trisomy could be considered an overt causative agent triggering NB development, since only a fraction (<10%) of patients with constitutional 2p duplication eventually develops NB [7–9]. To address the issue further, we have compared two patients with constitutional rearrangement at chromosome 2p involving MYCN but not ALK locus, of whom only one developed NB. We have found significant differences in gene copy number profile at MYCN genomic region. Areas of gains and losses at chromosome 2p24 were observed in the patient with NB (Figure 2). On somatic level, similar aberration, including MYCN gain, was detected in the NB sample. No other genetic event characteristic for NBs, including other segmental chromosomal aberration(s), LOHs or an ALK gene point mutation was found in the tumor. Metaphase FISH studies showed uneven distribution and variable degree of the gain in single cells reflecting the heterogeneous character of the tumor. Since secondary numerical and segmental chromosomal alterations are common findings in NB, this may explain why in qPCR MYCN copy number was lower in tumor vs. blood (Figure 2) given that the assay measures relative dosage of the genes.
The consequence of MYCN gain in NB remains unclear. Even though large studies did not show its prognostic significance  our data provide further evidence in favor of its role at early stage of NB development and tumor progression. In the light of the clinical variables: low-stage, neonatal age at diagnosis, histopathology subtype and lack of adverse genetic markers our patient should have been classified as a low-risk NB. However, the uncertainty with respect to the number of MYCN gene copies, eventually classified as MYCN gain, and the natural history of other NB patients with constitutional 2p duplication were the two rationales for choosing an intensified strategy of treatment to address the anticipated aggressive biology of the tumor. All previously published patients with partial 2p trisomy who were diagnosed with NB over the age of six months had already progressed to metastatic disease at the time of diagnosis [9, 11–13]. Unfortunately, MYCN amplification was assessed in three patients only (Figure 3). The results were discordant: a case of a stage 1 NB was found to have 3 copies of MYCN on array-CGH ; a patient with stage 4S NB was found to have MYCN gain by FISH  and the third child with stage 4 NB was found to have MYCN amplification presenting as multiple double minutes (dmin) on FISH examination .
The molecular evaluation of the MYCN genomic region allowed for detection of significant differences in gene copy number pattern at the 2p24 locus suggestive for the presence of a cryptic complex genomic rearrangement (CGG) in our NB patient. A number of models and processes have been proposed to be involved in the origin of CGGs . The ongoing debate seems to favor chromothripsis, the one-off event to be responsible for most of the structural aberrations in cancer . Likewise, the recent analysis of a series of patients with constitutional CGGs has shown involvement of end-joining mechanism of double-stranded DNA breaks resembling the chromothripsis-like chromosome catastrophes in their pathogenesis .
Moleenar et al.  were the first to report presence of chromothripsis in 11% of primary NBs, on the whole in older (>1.5 years) patients with MYCN amplified and solely advanced stage tumors. In one of ten reported tumors, chromothripsis resulted in amplification and very strong overexpression of MYCN. Further evaluation of high-risk NB by means of next-generation techniques has shown no recurrent fusion transcripts and presence of substantial local rearrangements in a minority of cases only . The later exclusively affected the vicinity of MYCN locus, with numerous complex copy number states and retention of heterozygosity in lower-copy number regions. Such a pattern of amplified/nonamplified regions within the MYCN amplicon was already observed in a series of NB cell lines . The striking common denominator for the aforesaid NB-related CGGs and the presented case is the presence of minute areas of gains and losses in the vicinity the MYCN gene. Blumirch et al. have shown that the boundaries of the CGGs involving MYCN detected in NBs, and also observed in the present case, cluster to the well known microhomology region: a common fragile site FRA2C on chromosome 2p24 (Figure 2).
Common fragile sites (cFS) are evolutionarily conserved AT-rich regions inherited within normal chromosomal structure well known for their relative high mutation rate . When exposed to environmental factors that interfere with DNA replication the accumulation of DNA secondary structures at cFS may give rise to double-strand breaks, what in consequence may generate structural chromosomal instability . Our results suggest, that the inherited unbalanced chromosomal aberration at 2p may give grounds for nonrandom clustering of chromosomal breaks at the FRA2C leading to MYCN amplicon formation.
To our knowledge, this is the first report of a case of a constitutional genomic instability at MYCN locus detected in an neonate with an inherited unbalanced chromosomal rearrangement and neuroblastoma and no other genomic alteration and/or known NB risk factor. It seems that the germinal chromosomal aberration encompassing MYCN locus without co-involvement of ALK gene was sufficient to trigger cancerogenesis.
A patient with 46,XX,der(18)t(2;18)(p24;q23)mat presenting distinct dysmorphic features (dolichocephaly, midfacial hypoplasia, large fontanella, hypotelorism, anteverted nostrils, prominent philtrium, microretrognathia), congenital defects (ASD, PDA, cervical ribs, bilateral postaxial polidactyly) and severe neonatal hypotonia was found to have a suprarenal lesion on neonatal sonography. Further image studies (MRI and metaiodobenzylguanidine (MIBG) scintiscan) as well as bone-marrow biopsy showed presence of a single solid tumor lying in the left suprarenal area, but with no sign of metastatic lesions or bone-marrow involvement. At the age of 2 months surgery was performed. In view of the final diagnosis of locoregional Schwannian stroma-poor poorly differentiated NB (low risk according to Shimada system and INRG consensus pretreatment classification) the patient started chemotherapy according to LINES 2009 (Low and Intermediate Risk Neuroblastoma European Study) protocol, however after two courses the parents declined from further oncological treatment. Moreover, after defining maternal origin of the translocation, the family refused further genetic evaluation. The patient remains alive 2.5 years later with no sign of disease recurrence.
The second patient with 46,XY,der(17)t(2;17)(p23;p13)dn, is a mildly dysmorphic boy with multiple congenital defects including lissencephaly, cryptorchidism, duplex ureter (ureter fissus). The patient is subject to regular oncological surveillance by means of image studies and periodical testing of urine catecholamine metabolite levels. The child is alive with no sign of neoplastic process at the age of 3.8 years.
DNA was isolated from the peripheral blood leukocytes of two patients with constitutional partial 2p trisomy and nine anonymous healthy female volunteers, which were utilized as the reference control DNA. Constitutional DNA samples used in array-CGH and qPCR experiments were isolated using QIAamp DNA Blood Midi Kit (Qiagen). Besides, tumor DNA, after verification of neoplastic cell content to be exceeding 80%, was extracted from a fresh-frozen neuroblastoma sample according to salting–out protocol .
Karyotyping and fluorescent in situ hybridization
Cytogenetic studies were performed using conventional GTG–banding of lymphocyte metaphase chromosomes at a 550 band level following standard protocol. Double-color fluorescent in situ hybridization (FISH) was performed on interphase nuclei of NB tumor touch imprints and on lymphocytes using Cytocell N-myc Amplification Probe LPS009 for MYCN gene copy number detection. In each analysis at least 60 nuclei were evaluated.
Targeted mutational analysis of ALK gene
Germline and somatic status of ALK at its mutational hot-spot (exons 23–25) was evaluated through direct sequencing (Applied Biosystem).
Array comparative genomic hybrydization
Array – CGH analysis of patients constitutional DNA and tumor DNA was at first performed using high – resolution Human CGH 2.1 M Whole-Genome Tiling Array and later expanded using Human CGH 385 K Chromosome 2 Tiling Array and Custom CGH/LOH 37×1.4 M Arrays (NimbleGen, Roche) following the instructions provided by manufacturer. Arrays were scanned with MS200 Microarray Scanner and analyzed using NimbleScan, SignalMap and Deva v1.2.1 software (NimbleGen, Roche). All identified genomic imbalances were verified in the database of genomic variants (DGV; http://dgv.tcag.ca; last accessed May 2013).
Quantitative real – time PCR
The results of microarray study were validated by quantitative real – time PCR (qPCR) performed on LightCycler480 System (Roche). Target genes: DDX1, MYCN, FAM49A, SMC6, NT5C1B, OSR1 within the duplicated region (2p24) were assessed against a control gene ZNF2 at 2q11.2 and two reference genes GPR15 (3q11.2) and ERMP1 (9p24.1). qPCR assays were performed using FastStart Universal Probe Master and specific FAM pre – labelled probes from Universal Probe Library (Roche). All samples were run in triplicates. The dosage of target genes relative to reference genes normalized to control DNA (same as reference DNA used for array-CGH study) was assessed.
Written informed consent was obtained from the legal guardians of the patient (parents) for the publication of the data presented in the report.
This work has been financed by the Polish Ministry of Science and Education grant N N401 197339.
This study makes use of data generated by the DECIPHER Consortium. A full list of centres who contributed to the generation of the data is available from http://decipher.sanger.ac.uk and via email from email@example.com. Funding for the project was provided by the Wellcome Trust.
- Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD: Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer 2012, 107: 1418–1422. 10.1038/bjc.2012.375PubMed CentralView ArticlePubMedGoogle Scholar
- White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM: Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005, 24: 2684–2694. 10.1038/sj.onc.1208306View ArticlePubMedGoogle Scholar
- Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, et al.: The genetic landscape of high-risk neuroblastoma. Nat Genet 2013. doi: 10.1038/ng.2529Google Scholar
- Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455: 967–970. 10.1038/nature07398View ArticlePubMedGoogle Scholar
- Deyell RJ, Attiyeh EF: Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet 1988, 204: 113–121.View ArticleGoogle Scholar
- Schwab M: MYCN in neuronal tumours. Cancer Lett 2004, 204: 179–187. 10.1016/S0304-3835(03)00454-3View ArticlePubMedGoogle Scholar
- Feenstra I, Fang J, Koolen DA, Siezen A, Evans C, Winter RM, Lees MM, Riegel M, de Vries BB, Van Ravenswaaij CM, Schinzel A: European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA); an online database for rare chromosome abnormalities. Eur J Med Genet 2006, 49: 279–291. 10.1016/j.ejmg.2005.10.131View ArticlePubMedGoogle Scholar
- Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, Van Vooren S, Moreau Y, Pettett RM, Carter NP DECIPHER: Database of chromosomal imbalance and phenotype in humans using ensembl resources. Am J Hum Genet 2009, 84: 524–533. 10.1016/j.ajhg.2009.03.010PubMed CentralView ArticlePubMedGoogle Scholar
- van Mater D, Knelson EH, Kaiser-Rogers KA, Armstrong MB: Neuroblastoma in a pediatric patient with a microduplication of 2p involving the MYCN locus. Am J Med Genet 2013, 161: 605–610. 10.1002/ajmg.a.35766View ArticleGoogle Scholar
- Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009, 10: 289–297.View ArticleGoogle Scholar
- Nagano H, Kano Y, Kobuchi S, Kajitani T: A case of partial 2p trisomy with neuroblastoma. Jinrui Idengaku Zasshi 1980, 25: 39–45. 10.1007/BF01876544View ArticlePubMedGoogle Scholar
- Patel JS, Pearson J, Willatt L, Andrews T, Beach R, Green A: Germline duplication of chromosome 2p and neuroblastoma. J Med Genet 1997, 34: 949–951. 10.1136/jmg.34.11.949PubMed CentralView ArticlePubMedGoogle Scholar
- Yuksel A, Seven M, Karaman B, Yilmaz S, Deviren A, Hacihanefioglu S, Basaran S: Neuroblastoma in a dysmorphic girl with a partial duplication of 2p caused by an unbalanced translocation. Clin Dysmorphol 2002, 11: 39–42. 10.1097/00019605-200201000-00008View ArticlePubMedGoogle Scholar
- Soh SY, Stavropoulos D, Bowdin S, Thorner P, Baruchel S, Malkin D, Meyn MS, Irwin M: Metachronous neuroblastoma in an infant with constitutional unbalanced translocation t(2;16)(p23; p13.3) involving ALK . Poster presentation at ANR Stockholm 2010. POC38Google Scholar
- Dowa Y, Yamamoto T, Abe Y, Kobayashi M, Hoshino R, Tanaka K, Aida N, Take H, Kato K, Tanaka Y, Ariyama J, Harada N, Matsumoto N, Kurosawa K: Congenital neuroblastoma in a patient with partial trisomy of 2p. J Pediatr Hematol Oncol 2006, 28: 379–382. 10.1097/00043426-200606000-00011View ArticlePubMedGoogle Scholar
- Liu P, Carvalho CMB, Hastings PJ, Lupski JR: Mechanisms for recurrent and complex human genomic rearrangements. Curr Opin Genet Dev 2012, 22: 211–220. 10.1016/j.gde.2012.02.012PubMed CentralView ArticlePubMedGoogle Scholar
- Forment JV, Kaidi A, Jackson SP: Chromothripsis and cancer: causes and consequence of chromosome shattering. Nature Rev Cancer 2012, 12: 663–670.View ArticleGoogle Scholar
- Kloosterman WP, Tavakoli-Yaraki M, van Roosmalen MJ, van Binsbergen E, Renkens I, Duran K, Ballarati L, Vergult S, Giardino D, Hansson K, Ruivenkamp CA, Jager M, van Haeringen A, Ippel EF, Haaf T, Passarge E, Hochstenbach R, Menten B, Larizza L, Guryev V, Poot M, Cuppen E: Constitutional chromothripsis rearrangements involve clustered double-stranded DNA breaks and nonhomologous repair mechanisms. Cell Rep 2012, 1: 648–655. 10.1016/j.celrep.2012.05.009View ArticlePubMedGoogle Scholar
- Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R: Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012, 483: 589–593. 10.1038/nature10910View ArticlePubMedGoogle Scholar
- Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, D'Addabbo P, Daniele G, L'Abbate A, Macchia G, Surace C, Kok K, Ullmann R, Purgato S, Palumbo O, Carella M, Ambros PF, Rocchi M: Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res 2010, 20: 1198–1206. 10.1101/gr.106252.110PubMed CentralView ArticlePubMedGoogle Scholar
- Blumrich A, Zapatka M, Brueckner LM, Zheglo D, Schwab M, Savelyeva L: The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers. Hum Mol Genet 2011, 20: 1488–1501. 10.1093/hmg/ddr027View ArticlePubMedGoogle Scholar
- Yunis JJ, Soreng A: Constiutive fragile sites and cancer. Science 1984, 226: 1199–1204. 10.1126/science.6239375View ArticlePubMedGoogle Scholar
- Schwartz M, Zlotorynski E, Kerem B: The molecular basis of common and rare fragile sites. Cancer Lett 2005, 232: 13–26.View ArticlePubMedGoogle Scholar
- Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16: 1215. 10.1093/nar/16.3.1215PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.